Boehringer Ingelheim Jascayd receives regulatory approval for progressive pulmonary fibrosis in China Ruchika Sharma11 Dec 2025 11:30 AM ISTIngelheim: Boehringer Ingelheim has announced that China's National Medical Products Administration (NMPA) has approved JASCAYD (nerandomilast) as the...
Boehringer Ingelheim advances next generation triple-agonist peptide for obesity Ruchika Sharma9 Dec 2025 11:30 AM ISTBoehringer Ingelheim has announced the advancement of BI 3034701, its long-acting potential first-in-class triple-agonist peptide, in development for...
Boehringer Ingelheim appoints Harsha Deshmukh to its Board of Managing Directors Ruchika Sharma29 Nov 2025 11:30 AM ISTIngelheim: Boehringer Ingelheim has announced that the Shareholders' Committee has appointed Harsha Deshmukh to the Board of Managing Directors....
Boehringer Ingelheim obtains two EU CVMP positive opinions for avian influenza vaccines Ruchika Sharma23 Nov 2025 3:45 PM ISTIngelheim: Boehringer Ingelheim has obtained positive opinions from the European Medicines Agency (EMA) recommending the granting of marketing...
Boehringer Ingelheim, CDR-Life enter into new agreement to develop autoimmune disease molecule Ruchika Sharma9 Nov 2025 11:30 AM ISTIngelheim: Boehringer Ingelheim and CDR-Life, Inc. have announced a new global licensing agreement to develop CDR-Life’s unique antibody based ...
Boehringer Ingelheim acquires license from Kyowa Kirin to develop autoimmune diseases treatment Ruchika Sharma31 Oct 2025 5:56 PM ISTGermany: Boehringer Ingelheim and Kyowa Kirin Co., Ltd. have announced that Boehringer Ingelheim has licensed a pre-clinical program from Kyowa...
Boehringer Ingelheim Jascayd gets nod in China for idiopathic pulmonary fibrosis Ruchika Sharma23 Oct 2025 3:00 PM ISTBoehringer Ingelheim has announced that China's National Medical Products Administration (NMPA) has approved JASCAYD (nerandomilast) as an oral...
Boehringer Ingelheim, AimedBio collaborate to develop ADC therapy for cancer Ruchika Sharma21 Oct 2025 11:59 AM ISTBoehringer Ingelheim and AimedBio, a biotechnology company specializing in the development of antibody-based therapeutics, have announced a global...
Boehringer Ingelheim Jascayd tablets approved by USFDA for idiopathic pulmonary fibrosis Ruchika Sharma14 Oct 2025 11:06 AM ISTIngelheim: Boehringer Ingelheim has received approval from the U.S. Food and Drug Administration (FDA) for JASCAYD (nerandomilast) tablets as an...
Boehringer Ingelheim Hernexeos approved in China for previously treated patients with HER2-mutant advanced NSCLC Ruchika Sharma2 Sept 2025 10:50 AM ISTBoehringer Ingelheim has received approval for HERNEXEOS (zongertinib tablets) from China's National Medical Products Administration (NMPA) as...
Boehringer Ingelheim, AnGes sign manufacturing agreement for HGF gene therapy product Ruchika Sharma21 Aug 2025 12:30 PM ISTIngelheim: Boehringer Ingelheim has announced the signing of a contract development and manufacturing agreement with AnGes Inc. for the drug...
Boehringer Ingelheim, Palatin Technologies to develop melanocortin receptor targeted treatment for retinal diseases Ruchika Sharma19 Aug 2025 10:30 AM ISTIngelheim: Boehringer Ingelheim and Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on...
